Aap Implantate : Press Release dated 30 June, 2017

aap: Update regarding antibacterial silver coating technology - Preparations for clinical human study under way

aapImplantate AG ('aap') provides an update on the recent developments regarding the aimed CE and FDA approval for its antibacterial silver coating technology. Based on the previous talks with the involved authorities as well as the internal development progress, aapwill initiate various further preparations for the implementation of a clinical human study in the second half of 2017. In addition, the coordination of the design and the extent of the human study with the competent authorities will be continued. The company will publish further details about the study at the beginning of 2018.

The internationally IP-protected silver coating technology developed by aapprotects the surface of implants from bacterial colonisation. The technology thus addresses one of the critical and not yet adequately solved problems of surgery: the reduction of infection risks when using metal implants. aap's silver coating technology has several unique selling propositions such as a high coating stability as well as a good biocompatibility and effectiveness. These properties have been demonstrated in a number of different test series. Furthermore, it is a cost-effective coating technology that is scalable to higher production volumes with reasonable expense as investments for the required coating machinery are relatively low.

As a platform technology aap's silver coating technology has a wide range of applications and can be used not only in orthopaedics but also in different further areas such as cardiology, dentistry or for medical instruments.

Along with preparing for the clinical human study aapis currently in talks with various global companies on potential joint development projects in the field of silver coating technology.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aapto be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aapdoes not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments